Join the conversation with Susan Cole, George Clinical’s Regional Head of Project Operations USA & Europe, and Prof. David Thomas of the Garvan Institute of Medical Research, covering the future of oncology trials and genomic profiling.
Genomic profiling is changing cancer medicine, enabling the mapping of the mutational circuitry of cancers. Dozens of highly effective therapies have changed treatment options for many cancers and have received regulatory approval. This evolution has driven the development of large-scale genomic profiling programs linked to biomarker-dependent therapeutic trials.
In Australia, a national precision oncology platform to enable large-scale genomic screening of cancer patients has been developed through an innovative non-profit company, Omico. George Clinical’s collaboration with Omico looks to harness the paradigm-shifting potential of this platform to change the way how oncology trials are conducted in Australia.
The webinar will also address:
• An introduction to the Omico platform
• Economic hurdles that can impact the way diagnostic algorithms and a standard of care are implemented
• The potential of genomic profiling to revolutionize clinical trial access to and for patients
• Operational barriers faced in the implementation of oncology trials and how these could be surpassed with a platform such as Omico